Banking newborn stem cells an option for
couples choosing gestational carrier
TRUMBULL, Conn., July 27,
2023 /PRNewswire/ -- CooperSurgical, a global leader
in fertility and women's health, announced that Chrissy Teigen, mom, New
York Times best-selling cookbook author, television host and
entrepreneur, selected Cord Blood Registry® (CBR®) to bank the
umbilical cord blood and cord tissue of her newborn, Wren Alexander
Stephens, who was born via gestational carrier in June.
"Expectant parents may be confused if they can preserve their
newborn's stem cells when they are using a surrogate or gestational
carrier. The process of collecting and storing cord blood and cord
tissue is no different for parents who are growing their families
through use of a gestational carrier versus a pregnancy carried by
the intended parent," stated board-certified OB/GYN and CBR
spokesperson, Dr. Christine
Sterling. "As Chrissy's example demonstrates, the option to
bank cord blood and tissue is still very much available to parents
who build their families in a wide variety of ways."
CBR and Teigen launched an educational campaign earlier this
year to raise awareness about the potential benefits of banking
newborn stem cells from cord blood and cord tissue. CBR is the
largest family newborn stem cell preservation company in the world,
helping parents store newborn stem cells from cord blood and cord
tissue for their children. CBR is the #1 choice for
parents1 and the most recommended cord blood
preservation company by OB/GYNs.2
"CBR is dedicated to educating families about the life-saving
potential of newborn stem cells, helping to provide them with
access to current treatments and future clinical therapies," stated
Holly Sheffield, President,
CooperSurgical. "We are delighted that our campaign is educating
more families that newborn stem cell preservation is a viable
option when using a gestational carrier, and we are proud to
continue working with Chrissy over the next several months."
For more information about CBR and the benefits of cord blood
banking, please visit www.cordblood.com/chrissy.
About CBR by CooperSurgical
Cord Blood Registry® (CBR®) is the
largest family newborn stem cell preservation company in the world,
helping parents store stem cells from cord blood and cord tissue
for their children. Founded in 1994, CBR is the #1 choice for
parents1 and most recommended by OB/GYNs for newborn
stem cell preservation.2 The company has released
over 700 samples intended for use in transplant medicine and
regulated investigational regenerative medicine applications. CBR
is here to help expand the possibilities of what newborn stem cell
therapies can do for families and give parents the confidence to
Bank on CBR™. More information can be found
at www.cordblood.com.
About CooperSurgical
CooperSurgical® is a leading
fertility and women's healthcare company dedicated to putting time
on the side of women, babies, and families at the healthcare
moments that matter most in life. CooperSurgical is at the
forefront of delivering innovative assisted reproductive technology
and genomic solutions that enhance the work of ART professionals to
the benefit of families. We currently offer over 600 clinically
relevant medical devices to women's healthcare providers, including
testing and treatment options.
CooperSurgical is a wholly-owned subsidiary of CooperCompanies
(NYSE: COO). CooperSurgical, headquartered in Trumbull,
CT, produces and markets a wide array of products and services for
use by women's health care clinicians. More information can be
found at www.coopersurgical.com.
About CooperCompanies
CooperCompanies ("Cooper") is a
global medical device company publicly traded on the NYSE (NYSE:
COO). Cooper operates through two business units, CooperVision and
CooperSurgical. CooperVision brings a refreshing perspective on
vision care with a commitment to developing a wide range of
high-quality products for contact lens wearers and providing
focused practitioner support. CooperSurgical is committed to
advancing the health of women, babies and families with its
diversified portfolio of products and services focusing on medical
devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of
more than 15,000 with products sold in over 130 countries. For more
information, please visit www.coopercos.com.
Disclaimer:
The use of cord blood is determined by the
treating physician and is influenced by many factors, including the
patient's medical condition, the characteristics of the sample, and
whether the cord blood should come from the patient or an
appropriately matched donor. Cord blood has established uses in
transplant medicine; however, its use in regenerative medicine is
still being researched. There is no guarantee that potential
medical applications being studied in the laboratory or clinical
trials will become available.
Cord tissue use is still in early research stages, and there is
no guarantee that treatments using cord tissue will be available in
the future. Cord tissue is stored whole. Additional processing
prior to use will be required to extract and prepare any of the
multiple cell types from cryopreserved cord tissue. Cbr Systems,
Inc.'s activities for New York
State residents are limited to collection of umbilical cord
tissue and long-term storage of umbilical cord–derived stem cells.
Cbr Systems, Inc.'s possession of a New
York State license for such collection and long-term storage
does not indicate approval or endorsement of possible future uses
or future suitability of these cells.
References:
- Internal source. Data on file.
- Blind survey, Egg Strategy, 10/19, funded by CBR.
Contact:
CooperSurgical
EvolveMKD
csi@evolvemkd.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chrissy-teigen-selects-cord-blood-registry-to-preserve-fourth-childs-newborn-stem-cells-301887809.html
SOURCE CooperSurgical®
